Showing results 1 to 1 of 1
Issue Date | Title | Journal Title |
---|---|---|
2023 | Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D | JOURNAL FOR IMMUNOTHERAPY OF CANCER |